Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants
Phase 2
Completed
- Conditions
- Meningitis, Meningococcal
- Registration Number
- NCT00314041
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
Infant phase: To determine the safety of and production of antibodies by a group C meningococcal conjugate vaccine (MnCC), when given at 2, 3, and 4 months of age with routine vaccines.
Booster phase: To compare the safety of and production of antibodies by MnCC with and without MMR and to compare the antibody response to that produced by a low dose of plain polysaccharide vaccine as a way of investigating immune memory
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 240
Inclusion Criteria
- Healthy infants 7-10 weeks of age eligible to receive routine immunization
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Antibody responses to MnCC and concomitant vaccines
- Secondary Outcome Measures
Name Time Method Safety and reactogenicity